Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.62 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.62 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.62 |
| ▸ | FAP | Q12884 | 1/20 | 0.62 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.62 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16307729 | 1.00 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL1798266 | 1.00 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL16104918 | 0.95 | DPP4 (0.56) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL13997176 | 0.95 | DPP4 (0.56) | DPP4DPP8DPP9FAPDPP7 | |
| Proline SCHEMBL7113049 | 0.82 | DPP4 (0.47) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL16314357 | 0.80 | DPP4 (0.59) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL18462323 | 0.79 | DPP4 (0.61) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL825679 | 0.78 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL6371844 | 0.78 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL30924754 | 0.78 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784400-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-1868991-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-1756051-B1 | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8008301-B2 | (2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4'-trifluoromethyl-biphenyl-4-yl)-methanone; treatment of nervous system disorder, obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| US-7951826-B2 | Obesity; cognition activators; narcolepsy | ELI LILLY AND COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| US-7846950-B2 | Histamine H3 receptor inhibitors, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-7705025-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-7696234-B2 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7632857-B2 | (3-Fluoro-4'-methanesulfonyl-biphenyl-4-yl)-[2-(S)-(2-(R)-methyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-methanone; treatment of obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1861360-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | disclosed |
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-02-19 | — | — | US | disclosed |
| EP-1805169-B1 | HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | JESUDASON CYNTHIA D | 2008-01-17 | — | — | US | disclosed |
| EP-1868991-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2006107661-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | HRH3, HCRTR1, HRH4 | DPP4 1032/4885DPP8 1587/4885DPP9 1088/4885 |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | HRH3, HRH4, HCRTR1 | DPP4 1198/4885DPP8 2479/4885DPP9 2552/4885 |
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | DPP4 1450/4885DPP8 1867/4885DPP9 1615/4885 |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | DPP4 1142/4885DPP8 1652/4885DPP9 1389/4885 |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | DPP4 1214/4885DPP8 1733/4885DPP9 1657/4885 |
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | HRH3, HRH4, HCRTR1 | DPP4 1280/4885DPP8 1970/4885DPP9 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.